• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatic oncology. >Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients
【24h】

Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients

机译：Regorafenib和Arrorce试验：肝细胞癌患者的新二线选择

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Dr Jordi Bruix speaks to Laura Dormer, Editorial Director: Dr Jordi Bruix is the Head of the Barcelona Clinic Liver Cancer (BCLC) group at the Hospital Clinic (University of Barcelona, Spain) and Director of the Network for Research in Liver and Digestive Disease (CIBEREHD) in the Spanish Research Institute. His research has changed the diagnosis and treatment of liver cancer. Major highlights include: development of the BCLC staging and treatment; development of diagnostic criteria for hepatocellular carcinoma; identification of the value of portal pressure in predicting prognosis after resection; and acting as principal investigator of the Phase III trials that have shown the benefits of chemoembolization, sorafenib and regorafenib for patients with liver cancer. He has authored the European Assoaciation for the Study of the Liver, American Association for the Study of Liver Diseases and World Gastroenterology Organization Practice Guidelines and the United Network for Organ Sharing hepatocellular carcinoma (HCC) diagnostic criteria.
机译：Jordi Bruix博士对Laura Dormer，编辑总监：Jordi Bruix博士是巴塞罗那临床肝癌（BCLC）集团的负责人，位于医院诊所（西班牙大学），肝脏和消化疾病研究网络主任（Ciberehd）在西班牙研究所。他的研究改变了肝癌的诊断和治疗。主要亮点包括：BCLC分期和治疗的发展;开发肝细胞癌诊断标准;鉴定入切除后预测预后的门位压力值;并作为第III期试验的主要调查员，该试验表明了肝癌患者的化疗栓塞，索拉非尼和雄酮的益处。他撰写了欧洲分配对肝病的研究，美国肝病和世界胃肠学组织实践指南和机箱的联合网络进行研究，用于共享肝细胞癌（HCC）诊断标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号